RF Pathway Inhibitor and MEK Inhibitor Combination for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pancreatic cancer are ineffective, and there is an urgent need for a novel approach to address the increasing incidence and mortality rates due to the complexity of the disease, particularly in terms of early detection and prognosis.
Innovation Solution
A method involving the administration of an RF pathway inhibitor, such as roseoflavin, potentially combined with a MEK inhibitor like trametinib, to inhibit the riboflavin pathway, offering a novel mechanism for treating or preventing pancreatic cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods are used for pancreatic cancer, then current standard therapies are applied, but treatment effectiveness is insufficient due to the intractable nature of the disease
Solution Approach 1:
The patent changes the therapeutic parameter from conventional cancer treatments to riboflavin pathway inhibition using roseoflavin. This parameter change targets a previously unexplored metabolic pathway in pancreatic cancer, thereby improving treatment effectiveness while introducing novel therapeutic approach
Solution Approach 2:
The patent uses roseoflavin as an intermediary substance that specifically inhibits the riboflavin pathway. This intermediary agent mediates the therapeutic effect by blocking a critical metabolic pathway unique to cancer cells, achieving effective treatment through a novel mechanism
2Reliability
If combination therapy with RF pathway inhibitor and MEK inhibitor is administered, then cancer cell growth suppression is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two therapeutic agents (roseoflavin and trametinib) into a combination therapy regimen. This merging of treatments targets multiple pathways simultaneously, enhancing cancer cell growth suppression through synergistic effects despite increased regimen complexity
Solution Approach 2:
The patent segments the treatment approach by targeting two distinct pathways (riboflavin pathway and MEK pathway) separately with specific inhibitors. This segmentation allows for precise targeting of different cancer cell mechanisms, improving overall suppression effectiveness while maintaining clear treatment boundaries
Data Source
AI summary
The present invention provides a method for treatment or prevention of cancer through novel action mechanism, namely, through inhibition of a riboflavin pathway. The method for treatment or prevention of cancer comprises administering an RF pathway inhibitor to a subject in need thereof.